Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis☆
Under an Elsevier user license
open archive
Abbreviations
DAA
directly acting antiviral agent
HCV
hepatitis C virus
IC50
inhibitory concentration 50%
IU/mL
international units per milliliter
LLD
lower limit of detection
LLQ
lower limit of quantification
P/R
peginterferon alfa/ribavirin
SVR
sustained virologic response
Keywords
Vaniprevir
Hepatitis C-genotype 1
Resistance-associated variants
Cited by (0)
- ☆
The parent study and the current analysis were sponsored and funded by Merck.
Copyright © 2013 Elsevier Inc. All rights reserved.